Sanofi-aventis

Sanofi

Kinga Boer

Geza Timari

Sandor Batori

Zoltan Kapui

Endre Mikus

Peter Aranyi

Katalin Urban-Szabo

Judit Vargane Szeredi

Katalin Gerber

Lajos T Nagy

Laszlo Balazs

Michel Finet

Tibor Szabo

Maria Balogh

Imre Bata

Erzsebet Walcz

Judit Bence

Felix Hajdu

Katalin Urban Szabo

Edit Susan

Geza Toth

Zoltán Kapui

Mária Balogh

Zsuzsanna Szamosvölgyi

Csaba Tomboly

Gábor Szeleczky

Olivier Finance

Sándor Batori

Lászlö Balazs

Péter Aranyi

Géza Timari

Géza Tímári

Géza Tóth

Csaba Tömböly

The present invention relates to the adenosine Areceptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.

Compounds

The present invention relates to an adenosine Areceptor ligand of the general formula (I).

Aminoquinoline derivatives and their use as adenosine A3 ligands

The invention relates to adenozin Areceptor ligands labeled with iodine isotops of mass number 125, within those favorably to antagonists and their isomers, to the experimental materials containing them, to a process for the preparation of the compounds of the general formula (I) and their isomers, to the new intermediates of the general formula (II) and to the preparation thereof.

Isotopically marked quinoline derivatives as adenosin A3 receptor ligands

The present invention relates to an adenosine Areceptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II&#x2033;), (III&#x2033;), (IV&#x2033;), (V&#x2033;), (VI&#x2033;), (VII&#x2033;), (VIII&#x2033;) and (XIII&#x2033;) and their preparation.

The present invention relates to adenosine Areceptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Triazolo-quinolin derivatives useful as adenosine receptor ligands

This invention is directed to a compound of formula (I), wherein R, R, R, R, R, R, R, R, R, R, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine Areceptor ligand preferably an antagonist.

Imidazoquinoline derivatives as adenosine A3 receptor ligands

The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Growing community of inventors

Pomaz, Hungary

Kinga Boer